Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Susanna B. Park,David Goldstein,Arun V. Krishnan,Cindy S.-Y. Lin,Michael Friedlander,James T. Cassidy,Martin Koltzenburg,Matthew C. Kiernan +7 more
Reads0
Chats0
TLDR
This review will address the increasing importance and challenge of chemotherapy‐induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers.Abstract:
With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long-term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy-induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy-induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies. CA Cancer J Clin 2013;63:419-437. ©2013 American Cancer Society, Inc.read more
Citations
More filters
Journal ArticleDOI
Reactive Oxygen Species (ROS)-Based Nanomedicine.
Bowen Yang,Yu Chen,Jianlin Shi +2 more
TL;DR: In this article, the intrinsic biochemical properties of reactive oxygen species (ROS) underlie the mechanisms that regulate various physiological functions of living organisms, and they play an essential role in regulating various physiological function.
Journal ArticleDOI
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
Marta Seretny,Gillian L. Currie,Emily S. Sena,Sabrina Ramnarine,Robin Grant,Malcolm R. Macleod,Leslie A. Colvin,Marie Fallon +7 more
TL;DR: A systematic review of studies reporting the prevalence of Chemotherapy‐induced peripheral neuropathy identified 31 studies with data from 4179 patients and identified a number of genetic and clinical risk factors that require further study.
Journal ArticleDOI
Microbiota: a key orchestrator of cancer therapy.
Soumen Roy,Giorgio Trinchieri +1 more
TL;DR: The evidence for the ability of the microbiota to modulate chemotherapy, radiotherapy and immunotherapy is discussed with a focus on the microbial species involved, their mechanism of action and the possibility of targeting the microbiome to improve anticancer efficacy while preventing toxicity.
Journal ArticleDOI
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy.
Renata Zajączkowska,Magdalena Kocot-Kępska,Wojciech Leppert,Anna Wrzosek,Joanna Mika,Jerzy Wordliczek +5 more
TL;DR: A better understanding of the risk factors and underlying mechanisms of CIPN is needed to develop effective preventive and therapeutic strategies and the neurotoxicity mechanisms of the most common antineoplastic agents are reviewed.
Journal ArticleDOI
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Hana Starobova,Irina Vetter +1 more
TL;DR: This review focusses on the commonly used antineoplastic substances oxaliplatin, cisPlatin, vincristine, docetaxel, and paclitaxel which interfere with the cancer cell cycle—leading to cell death and tumor degradation—and cause severe acute and chronic peripheral neuropathies.
References
More filters
Journal ArticleDOI
Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers.
Bruno Giometto,Wolfgang Grisold,Roberta Vitaliani,Francesc Graus,Jérôme Honnorat,Guido Bertolini +5 more
TL;DR: The study results confirm that PNS influences oncologic patient survival, and elucidate the clinical evolution of paraneoplastic cerebellar syndrome according to the onconeural antibodies present.
Journal ArticleDOI
Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum–DNA binding
TL;DR: Oxaliplatin-induced DRG death was associated with the morphological characteristics of apoptosis defined by 4'-6-diamidino-2-phenylindole and annexin/propidium iodide staining and death was completely inhibited by the caspase inhibitor z-VAD-fmk.
Journal ArticleDOI
Chemotherapy-Induced Neuropathy and Its Association With Quality of Life Among 2- to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry
Floortje Mols,Tonneke Beijers,Valery E.P.P. Lemmens,Corina van den Hurk,Gerard Vreugdenhil,Lonneke V. van de Poll-Franse +5 more
TL;DR: Two to 11 years after diagnosis of CRC, neuropathy-related symptoms are still reported, especially sensory symptoms in the lower extremities among those treated with oxaliplatin, and future studies should focus on prevention and relief of chemotherapy-induced neuropathy.
Journal ArticleDOI
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,Anthony Boral,Dixie-Lee Esseltine,Patrick Y. Wen,Patrick Y. Wen,Anthony A. Amato,Anthony A. Amato,Kenneth C. Anderson,Jesús F. San Miguel +20 more
TL;DR: Bortezomib‐associated peripheral neuropathy is manageable and reversible in most patients with relapsed myeloma, and dose modification using a specific guideline improves peripheral Neuropathy management without adversely affecting outcome.
Journal ArticleDOI
Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy
TL;DR: The acute neurological symptoms reflect a state of peripheral nerve hyperexcitability that likely represents a transient oxaliplatin‐induced channelopathy that causes an axonal neuropathy similar to other platinum‐based chemotherapeutic agents.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more